The SPDR S&P Biotech ETF (XBI) and Invesco Biotechnology & Genome ETF (PBE) offer distinct investment strategies in the biotech sector. XBI employs a modified equal-weight methodology, investing in over 100 biotech firms, which led to a significant 72.6% gain over the past year, as it amplifies performance during bullish conditions. In contrast, PBE focuses on a more concentrated portfolio of about 30 stocks, weighted towards profitable companies, yielding a 34.7% return, making it more stable during downturns. Year-to-date, XBI outperformed PBE, but both funds have similar returns over the past five years. Investors seeking growth may prefer XBI, while those prioritizing stability might lean towards PBE. Factors like interest rate changes could influence future performance trends.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://247wallst.com/investing/etf/2026/07/24/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins/
